---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125927"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:57:52.791993+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics Q3 net loss $21.7M, cash $257.2M; losmapimod halted, PIONEER trial ongoing

## Summary
- Net loss $21.7M in Q3 2024 vs $24.0M loss in Q3 2023; R&D expenses down to $14.6M from $18.2M.
- Cash $257.2M as of Sept 30, 2024, up from $236.2M at Dec 31, 2023, due to $80M Sanofi upfront.
- Phase 1b PIONEER trial for pociredir (SCD) advancing; Cohorts 3 (12mg) and 4 (20mg) planned; data expected 2025.
- Losmapimod development suspended after Phase 3 REACH failure; company refocuses on pociredir and aplastic anemias.
- Cash runway into at least 2027; FY2025 cash burn guided at $55-65M; expects ~$240M cash at end of 2024.

## SEC filing metadata
- accession: 0000950170-24-125927
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017024125927/0000950170-24-125927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017024125927/fulc-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125927
- JSON: https://secwatch.observer/filing/0000950170-24-125927.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125927.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.